Lantheus (NASDAQ:LNTH) Given New $122.00 Price Target at B. Riley

Lantheus (NASDAQ:LNTH - Free Report) had its target price lowered by B. Riley from $127.00 to $122.00 in a research report released on Friday morning,Benzinga reports. The brokerage currently has a buy rating on the medical equipment provider's stock. B. Riley also issued estimates for Lantheus' Q3 2025 earnings at $1.51 EPS.

Other equities research analysts have also recently issued research reports about the stock. StockNews.com cut shares of Lantheus from a "buy" rating to a "hold" rating in a research report on Thursday, November 21st. The Goldman Sachs Group initiated coverage on shares of Lantheus in a research note on Wednesday, December 18th. They issued a "buy" rating and a $143.00 price target on the stock. Truist Financial increased their price objective on shares of Lantheus from $120.00 to $127.00 and gave the company a "buy" rating in a report on Thursday, February 27th. Finally, JMP Securities reaffirmed a "market outperform" rating and issued a $112.00 target price on shares of Lantheus in a report on Tuesday, January 14th. One analyst has rated the stock with a hold rating and seven have issued a buy rating to the company's stock. According to data from MarketBeat, Lantheus presently has a consensus rating of "Moderate Buy" and an average price target of $129.43.

Lantheus Trading Up 0.3 %

Lantheus stock traded up $0.33 during mid-day trading on Friday, hitting $99.77. The stock had a trading volume of 529,526 shares, compared to its average volume of 935,433. Lantheus has a one year low of $57.92 and a one year high of $126.89. The firm has a market capitalization of $6.83 billion, a P/E ratio of 16.60 and a beta of 0.38. The firm's 50 day moving average is $92.91 and its 200 day moving average is $96.45.

Lantheus (NASDAQ:LNTH - Get Free Report) last released its quarterly earnings data on Thursday, February 27th. The medical equipment provider reported $1.34 earnings per share for the quarter, missing analysts' consensus estimates of $1.57 by ($0.23). The business had revenue of $391.11 million during the quarter, compared to the consensus estimate of $376.61 million. Lantheus had a return on equity of 44.29% and a net margin of 28.57%. As a group, equities research analysts forecast that Lantheus will post 6.01 earnings per share for the current year.

Insider Transactions at Lantheus

In related news, Director Mary Anne Heino sold 53,107 shares of the firm's stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $94.35, for a total value of $5,010,645.45. Following the completion of the sale, the director now directly owns 440,399 shares in the company, valued at $41,551,645.65. This trade represents a 10.76 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Robert J. Jr. Marshall sold 10,000 shares of the business's stock in a transaction on Monday, March 17th. The shares were sold at an average price of $100.52, for a total transaction of $1,005,200.00. Following the transaction, the chief financial officer now owns 113,860 shares in the company, valued at $11,445,207.20. This trade represents a 8.07 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 64,109 shares of company stock worth $6,110,806 in the last three months. Insiders own 1.50% of the company's stock.

Institutional Investors Weigh In On Lantheus

Institutional investors have recently made changes to their positions in the company. Wilmington Savings Fund Society FSB purchased a new stake in Lantheus in the 3rd quarter worth about $25,000. Kestra Investment Management LLC bought a new position in shares of Lantheus during the fourth quarter valued at approximately $27,000. Summit Securities Group LLC purchased a new stake in shares of Lantheus in the fourth quarter worth approximately $37,000. UMB Bank n.a. lifted its stake in shares of Lantheus by 31.5% during the 4th quarter. UMB Bank n.a. now owns 559 shares of the medical equipment provider's stock worth $50,000 after acquiring an additional 134 shares during the last quarter. Finally, Parkside Financial Bank & Trust boosted its holdings in Lantheus by 49.4% during the 4th quarter. Parkside Financial Bank & Trust now owns 847 shares of the medical equipment provider's stock valued at $76,000 after acquiring an additional 280 shares during the period. Institutional investors own 99.06% of the company's stock.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.